Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA4089316
Max Phase: Preclinical
Molecular Formula: C44H68ClN5O8
Molecular Weight: 830.51
Molecule Type: Small molecule
Associated Items:
ID: ALA4089316
Max Phase: Preclinical
Molecular Formula: C44H68ClN5O8
Molecular Weight: 830.51
Molecule Type: Small molecule
Associated Items:
Canonical SMILES: CC[C@H](C)[C@H]1C(=O)N2CCC[C@H]2C(=O)O[C@H](C(C)(C)C)C[C@@H](C)C[C@H](O)[C@H](C)C(=O)N2CCC(CC2)C(=O)N[C@@H](Cc2ccc(Cl)cc2)C(=O)N(C)[C@@H](C)C(=O)N1C
Standard InChI: InChI=1S/C44H68ClN5O8/c1-11-27(3)37-42(56)50-20-12-13-34(50)43(57)58-36(44(6,7)8)24-26(2)23-35(51)28(4)39(53)49-21-18-31(19-22-49)38(52)46-33(25-30-14-16-32(45)17-15-30)41(55)47(9)29(5)40(54)48(37)10/h14-17,26-29,31,33-37,51H,11-13,18-25H2,1-10H3,(H,46,52)/t26-,27-,28-,29-,33-,34-,35-,36-,37-/m0/s1
Standard InChI Key: NRFKHZODSXPWQQ-LRNUZRBOSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Small molecule | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 830.51 | Molecular Weight (Monoisotopic): 829.4756 | AlogP: 4.70 | #Rotatable Bonds: 4 |
Polar Surface Area: 156.87 | Molecular Species: NEUTRAL | HBA: 8 | HBD: 2 |
#RO5 Violations: 1 | HBA (Lipinski): 13 | HBD (Lipinski): 2 | #RO5 Violations (Lipinski): 2 |
CX Acidic pKa: 12.43 | CX Basic pKa: | CX LogP: 4.64 | CX LogD: 4.64 |
Aromatic Rings: 1 | Heavy Atoms: 58 | QED Weighted: 0.33 | Np Likeness Score: 0.96 |
1. Onda Y, Masuda Y, Yoshida M, Doi T.. (2017) Conformation-Based Design and Synthesis of Apratoxin A Mimetics Modified at the α,β-Unsaturated Thiazoline Moiety., 60 (15): [PMID:28682609] [10.1021/acs.jmedchem.7b00833] |
Source(1):